Close Menu

In this week's PNAS Early Edition, the University of Alberta's Ling-ju Lin and Michael Schultz discuss promoter-targeted Rtt109 repression of ARG1 via "silencing a pathway of transcriptional activation that depends on ASF1." Lin and Schultz show that the intensity of ARG1 transcription "at its induced and repressed set points is controlled by different mechanisms of functional interplay between Rtt109 and Asf1."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.